COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  Meta AnalysisMeta
  Global AdoptionAdoption
  Submit FeedbackFeedback
    
  
Database of all ivermectin COVID-19 studies. 97 studies, 60 peer reviewed, 60 with results comparing treatment and control groups. Submit updates/corrections below. FLCCC provides treatment recommendations.
 
Search:  
Restrict:    All    Early    Late    Prophylaxis
6/18
Early, Late, PrEP, PEP Covid Analysis (Preprint) (meta analysis) meta-analysis v90 Ivermectin for COVID-19: real-time meta analysis of 60 studies
Details   • 95% of 39 early treatment and prophylaxis studies report positive effects (93% of all 60 studies). 28 studies show statistically significant improvements in isolation. • Random effects meta-analysis with pooled effects using the most s..
6/18
Early Krolewiecki et al., EClinicalMedicine, doi:10.1016/j.eclinm.2021.100959 (Peer Reviewed) ventilation, ↑151.9%, p=1.00 Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial
Details   Proof of concept RCT with 30 ivermectin patients and 15 control patients, showing a concentration dependent antiviral activity, but no significant difference in clinical outcomes. There was no significant difference in viral load reductio..
6/15
Review Zaidi et al., The Journal of Antibiotics, doi:10.1038/s41429-021-00430-5 (Review) (Peer Reviewed) review The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article
Details   Extensive review of 20 mechanisms of action of ivermectin for SARS-CoV-2.
6/15
Early Aref et al., International Journal of Nanomedicine, doi:10.2147/IJN.S313093 (Peer Reviewed) recov. time, ↓63.2%, p=0.0001 Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19
Details   RCT 114 patients in Egypt, 57 treated with ivermectin mucoadhesive nanosuspension intranasal spray, showing faster recovery and viral clearance with treatment. NCT04716569.
6/6
N/A Hariyanto et al., Reviews In Medical Virology, doi:10.1002/rmv.2265 (Peer Reviewed) death, ↓69.0%, p=0.001 Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies
Details   Systematic review and meta analysis of 19 RCTs showing mortality RR 0.31 [0.15-0.62].
6/2
Late Abd-Elsalam et al., Journal of Medical Virology, doi:10.1002/jmv.27122 (Peer Reviewed) death, ↓25.0%, p=0.70 Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study
Details   RCT 164 hospitalized patients in Egypt showing lower mortality and shorter hospitalization, but without statistical significance. There were no serious adverse effects. Authors suggest the low dosage may have resulted in lower efficacy th..
5/25
N/A Roman et al., medRxiv, doi:10.1101/2021.05.21.21257595 (Preprint) (meta analysis) meta-analysis Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
Details   Severely flawed meta analysis, incorrect at first glance. Authors cherry-pick to include only 4 studies reporting non-zero mortality and they claim a mortality RR of 1.11 [0.16-7.65]. However, they report incorrect values for Niaee et a..
5/18
In Vitro Mountain Valley MD (Preprint) (In Vitro) in vitro Mountain Valley MD Receives Successful Results From BSL-4 COVID-19 Clearance Trial on Three Variants Tested With Ivectosol™
Details   In Vitro and mouse study with human ACE2 cells, using solubilized ivermectin with Ivectosol™, showing antiviral effect with B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2. The ability to inject ivermectin potentially reduces the onset ..
5/12
News FLCCC Public Statement (News) news FLCCC Alliance Statement on the Irregular Actions of Public Health Agencies and the Widespread Disinformation Campaign Against Ivermectin
Details   Analysis of the ivermectin recommendations from WHO and others, and a call to action for all citizens, scientists, and media to counter false information. Whistleblowers can submit anonymous reports and images at the bottom of this page.
5/10
Early Faisal et al., The Professional Medical Journal, doi:10.29309/TPMJ/2021.28.05.5867 (Peer Reviewed) no recov., ↓68.4%, p=0.005 Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19
Details   RCT 100 outpatients in Pakistan, 50 treated with ivermectin, showing faster recovery with ivermectin. All patients received AZ, zinc, vitamin C, vitamin D, and paracetemol. Details of randomization were not provided. No mortality or hospi..
5/5
In Vitro Zatloukal et al. (News) (In Vitro) news News report on In Vitro results from the research institute of Prof. Zatloukal
Details   News report on In Vitro results from the research institute of Prof. Zatloukal, showing that "ivermectin was able to reduce virus replication by a factor of 1,000 even at low concentrations".
5/5
In Silico Qureshi et al., Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1906750 (Peer Reviewed) Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications
Details   In Silico study showing inhibition of importin-α1 by ivermectin, which disrupts SARS-CoV-2 replication.
5/4
Meta Karale et al., medRxiv, doi:10.1101/2021.04.30.21256415 (Preprint) (meta analysis) meta-analysis A Meta-analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation and Adverse Effects with Ivermectin Use in COVID-19 Patients
Details   Systematic review and meta analysis with 30 studies included in quantitative analysis, showing mortality OR 0.39 [0.22-0.70]. Subgroup analysis of trials with severity data showed mortality OR 0.10 [0.03-0.33] for mild/moderate cases.
5/3
Early Merino et al., SocArXiv Papers, doi:10.31235/osf.io/r93g4 (Preprint) hosp., ↓74.4%, p<0.001 Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City
Details   Analysis of Mexico City's use of an ivermectin-based medical kit, showing significantly lower hospitalization with use. Authors use logistic-regression models with matched observations, including adjustments for age, sex, COVID severity, ..
4/30
Review Kory et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377 (Review) (Peer Reviewed) (meta analysis) review Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Details   Review of ivermectin trials and epidemiological data, concluding that ivermectin is effective for prophylaxis and treatment, and should be globally and systematically deployed in the prevention and treatment of COVID-19.
4/29
Late Ahsan et al., Cureus, doi:10.7759/cureus.14761 (Peer Reviewed) death, ↓50.0%, p=0.03 Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan
Details   Retrospective 165 hospitalized patients in Pakistan showing unadjusted lower mortality with combined ivermectin and doxycycline treatment. Details of the ivermectin group compared to other patients are not provided, however ivermectin was..
4/19
Review DiNicolantonio et al., Open Heart, doi:10.1136/openhrt-2021-001655 (Review) (Peer Reviewed) review Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors
Details   Review suggesting that the effectiveness of ivermectin in the cytokine storm phase of COVID-19 may be, at least in part, an anti-inflammatory effect mediated by increased activation of glycine receptors on leukocytes and possibly vascular..
4/17
Early Loue et al., J. Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510202 (Peer Reviewed) death, ↓70.0%, p=0.34 Ivermectin and COVID-19 in Care Home: Case Report
Details   Small quasi-randomized (patient choice) study with 25 PCR+ patients in a nursing home offered ivermectin, of which 10 chose to be treated. The mean age was 83.5 in the treatment group and 81.8 in the control group. There was lower mortali..
4/16
PrEPPEP Morgenstern et al., medRxiv, doi:10.1101/2021.04.10.21255248 (Preprint) hosp., ↓80.0%, p=0.50 Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylactic method in Healthcare Workers
Details   Propensity matched retrospective prophylaxis study of healthcare workers in the Dominican Republic showing significantly lower cases with treatment, and no hospitalization with treatment (versus 2 in the PSM matched control group). The ca..
4/14
PrEPPEP Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035 (Peer Reviewed) severe case, ↓49.8%, p=0.01 Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
Details   Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower symptomatic cases, and lower confirmed cases of COVID-19 with all treatments (ivermectin, HCQ, PVP-I, and Zinc + vitamin C) compared to vitamin ..
4/10
In Silico Bello et al., Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1911857 (Peer Reviewed) Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets
Details   In Silico analysis finding that the in vitro activity of ivermectin may explained by acting as an inhibitor of importin-α, dimeric 3CLpro, and Nsp9.
4/3
Review Turkia, M., Research Gate (Review) (Preprint) review A timeline of ivermectin-related events in the COVID-19 pandemic
Details   An extensive timeline of ivermectin-related events from April 2020 to March 2021 including studies, news, health authority decisions, biased news coverage, and censorship. The author concludes that in a broader historical perspective, th..
4/1
Early Mourya et al., Int. J. Health and Clinical Research (Peer Reviewed) viral+, ↓89.4%, p<0.0001 Comparative Analytical Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in Index Medical College Hospital and Research Center, Indore, India
Details   Retrospective 100 patients in India with 50 treated with ivermectin, and SOC for all patients including HCQ+AZ, showing much higher viral clearance with ivermectin. Baseline clinical status was worse in the control group. Time of testing ..
3/30
Review Wehbe et al., Front. Immunol., doi:10.3389/fimmu.2021.663586 (Review) (Peer Reviewed) review Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities
Details   Review of how ivermectin was identified for use in COVID-19, mechanisms of action, and selected clinical trials.
3/30
Early Chahla et al., Research Square, doi:10.21203/rs.3.rs-495945/v1 (original preprint 3/30) (Preprint) no disch., ↓86.9%, p=0.004 Cluster Randomised Trials - Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers
Details   Cluster RCT outpatients in Argentina showing signficantly faster recovery with ivermectin. There were no deaths. Cluster RCT where outpatients in Tucumán were assigned to the ivermectin group and outpatients from San Miguel de Tucumán and..
3/29
Meta Kow et al., Pharmacological Reports, doi:10.1007/s43440-021-00245-z (Peer Reviewed) (meta analysis) meta-analysis The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis
Details   Small meta analysis of 6 RCTs showing mortality OR 0.21 [0.11-0.42]. Authors do not include two more recent RCTs with mortality results, 10 other studies with mortality results, and a total of 42 other studies including other outcomes. Au..
3/26
PrEPPEP Tanioka et al., medRxiv, doi:10.1101/2021.03.26.21254377 (Preprint) death, ↓88.2%, p=0.002 Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?
Details   Retrospective study of the 31 onchocerciasis-endemic countries using the community-directed treatment with ivermectin (CDTI) and the 22 non-endemic countries in Africa, showing significantly lower mortality per capita in the countries us..
3/25
In Silico Udofia et al., Network Modeling Analysis in Health Informatics and Bioinformatics, doi:10.1007/s13721-021-00299-2 (Peer Reviewed) In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV
Details   In Silico analysis finding that ivermectin had the highest binding energy against the 3CLpro of SARS-CoV-2 and RdRps of both SARS-CoV and SARS-CoV-2.
3/25
In Silico Choudhury et al., Future Medicine, doi:10.2217/fvl-2020-0342 (Peer Reviewed) Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach
Details   In Silico analysis finding that ivermectin has high binding affinity for the SARS-CoV-2 viral spike protein, main protease, replicase, and human TMPRSS2 receptors.
3/25
Late Huvemek Press Release (Preprint) no improv., ↓31.6%, p=0.28 Kovid-19 - Huvemek® Phase 2 clinical trial
Details   Phase 2 results from a multicenter RCT of hospitalized patients in Bulgaria showing faster viral clearance, greater clinical improvement, and improved biomarkers with treatment. Ivermectin was taken on an empty stomach, potentially reduci..
3/24
Review Yagisawa et al., The Japanese Journal of Antibiotics, 74-1, Mar 2021 (Review) (Peer Reviewed) review Global trends in clinical studies of ivermectin in COVID-19
Details   Review of ivermectin for COVID-19. Authors note that Kitasato University's project was expanded in response to the results of Caly et al. which had left questions regarding in vivo therapeutic levels, and the results of those studies were..
3/21
Early Emmerich et al., Int. J. Environ. Res. Public Health, doi:10.3390/ijerph18073371 (Peer Reviewed) Comparisons between the Neighboring States of Amazonas and Pará in Brazil in the Second Wave of COVID-19 Outbreak and a Possible Role of Early Ambulatory Treatment
Details   Comparison between the two largest neighboring states in Brazil, Amazonas and Pará, showing more than 5 times lower mortality in Pará during the second wave when the Pará government supported early treatment and Amazonas did not, compared..
3/18
Late Del Franco et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1008 (Peer Reviewed) Ivermectin in Long-Covid Patients: A Retrospective Study
Details   Retrospective 856 patients previously admitted to hospital for COVID-19 in Argentina, finding that ivermectin improved recovery from "long covid" symptoms.
3/12
Early Roy et al., medRxiv, doi:10.1101/2021.03.08.21252883 (Preprint) recov. time, ↓5.6%, p=0.87 Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study
Details   Retrospective database analysis of 56 mild COVID-19 patients, all treated with vitamin C, vitamin D, and zinc, comparing ivermectin + doxycycline (n=14), AZ (n=13), HCQ (n=14), and SOC (n=15), finding that all groups recover quickly, and ..
3/11
Meta Nardelli et al., Signa Vitae, doi:10.22514/sv.2021.043 (Peer Reviewed) (meta analysis) death, ↓79.5%, p<0.0001 Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?
Details &n